Methylene Chloride

Methylene Chloride

SCHEMBL537651

C1CCOCC1.C1CCOCC1.ClCCl

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
TTR P02766 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylene Chloride SCHEMBL27973738 1.00
Cyclohexane SCHEMBL1742381 1.00 ALDH1A1 (0.61) ALDH1A1TTRTSHR
Dioxane SCHEMBL23167499 0.96 ALDH1A1 (0.57) ALDH1A1TTRTSHR
Tetrahydrofuran SCHEMBL9077806 0.96 ALDH1A1 (0.67) ALDH1A1TTRTSHR
Tetrahydrofuran SCHEMBL40243 0.96
Tetrahydrofuran SCHEMBL6848959 0.92
Tetrahydrofuran SCHEMBL2395526 0.86 ALDH1A1 (0.53) ALDH1A1TTRTSHR
Tetrahydrofuran SCHEMBL5106977 0.85
SCHEMBL87670 0.83 ALDH1A1 (0.89) ALDH1A1TTRTSHR
SCHEMBL2848269 0.83 ALDH1A1 (0.89) ALDH1A1TTRTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179298-A1 Chemical process for the preparation of intermediates to obtain n-formyl hydroxy-lamine compounds NOVARTIS AG (CH) 2007-08-02 US claimed
EP-1599440-A2 CHEMICAL PROCESS FOR THE PREPARATION OF INTERMEDIATES TO OBTAIN N-FORMYL HYDROXYLAMINE COMPOUNDS Novartis AG (CH) 2005-11-30 EP claimed
WO-2004076053-A2 CHEMICAL PROCESS FOR THE PREPARATION OF INTERMEDIATES TO OBTAIN N-FORMYL HYDROXYLAMINE COMPOUNDS NOVARTIS AG (CH) 2004-09-10 WO claimed
US-8343961-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-01-01 US disclosed
EP-2414361-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS ArQule, Inc. (US) 2012-02-08 EP disclosed
EP-1439175-B1 PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF EISAI R&D MAN CO LTD (JP) 2011-04-27 EP disclosed
EP-2246344-A1 Pyrimidine compounds and medicinal composition thereof Eisai R&D Management Co., Ltd. (JP) 2010-11-03 EP disclosed
US-20100273901-A1 MOLECULE SULFONATION PROCESS AEGIS BIOSCIENCES LLC (US) 2010-10-28 US disclosed
WO-2010114894-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO disclosed
US-20100249115-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
CN-101730679-A Molecular sulfonation process AEGIS BIOSCIENCES LLP 2010-06-09 CN disclosed
EP-0749039-A1 Imaging element comprising an auxiliary layer containing solvent-dispersible polymer particles EASTMAN KODAK COMPANY (US) 1996-12-18 EP disclosed
EP-0749041-A1 Imaging element comprising an electrically-conductive layer and a protective overcoat layer containing solvent-dispersible polymer particles EASTMAN KODAK COMPANY (US) 1996-12-18 EP disclosed
US-4394386-A Fluorinated carbamate insecticides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1983-07-19 US disclosed
US-4393074-A Fluorinated carbamate insecticides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1983-07-12 US disclosed
US-4323578-A Fluorinated carbamate insecticides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1982-04-06 US disclosed
EP-0026569-A1 Fluorinated carbamates, processes for their preparation, insecticidal compositions comprising them, and controlling insects thereby E.I. DU PONT DE NEMOURS AND COMPANY (US) 1981-04-08 EP disclosed
US-4093652-A REACTING A CARBAMOYL FLOURIDE WITH AN ORGANIC DITHIOCHLORIDE UNION CARBIDE CORPORATION (US) 1978-06-06 US disclosed
US-4091016-A Thiosulfenylcarbamoyl halides UNION CARBIDE CORPORATION (US) 1978-05-23 US disclosed
US-3984397-A CYCLIZATION FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249115-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CYP11B2, GABBR1, CNR1 ALDH1A1 931/4885TTR 4584/4885TSHR 1855/4885
US-20070179298-A1 Chemical process for the preparation of intermediates to obtain n-formyl hydroxy-lamine compounds HAO1, LMNA, HAO2 ALDH1A1 765/4885TTR 3020/4885TSHR 4123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.